Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanib Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib Gastrointestinal disease known to interfere with absorption History of malabsorption or other clinically significant metabolic dysfunction that may interfere with absorption of oral study treatment Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of the study drug. Must not have a gastrointestinal condition that would interfere with absorption Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs Has gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the Investigator. Gastrointestinal (GI) condition which could impair absorption of study medication or inability to ingest study medication Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus Presence of conditions that will interfere significantly with the absorption of drugs A condition that would interfere with enteric absorption Any gastrointestinal or metabolic condition that could interfere with absorption of oral medication Gastrointestinal condition that could interfere with the swallowing or absorption of study medication Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs Presence of gastrointestinal disease that would significantly affect compound absorption. Patients with any severe gastrointestinal or metabolic condition which could interfere with the \r\nabsorption of oral study medications. Gastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs. Presence of a gastrointestinal condition that may affect drug absorption Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib Any coexistent medical condition interfering with drug absorption Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs Current or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening) Subjects with significant gastrointestinal abnormalities that may affect absorption (e.g., gastric bypass, short gut syndrome). For oral cohorts: The subject has gastrointestinal disease or has had a procedure that is expected to interfere with the oral absorption or tolerance of the study drug (e.g., functionally relevant gastrointestinal obstruction, mucositis/stomatitis, or frequent vomiting). Has presence of a gastrointestinal condition that may affect drug absorption Gastrointestinal abnormalities causing impaired absorption precluding administration of oral medications Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy) Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinib Malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of the study drug Patients with any condition likely to interfere with absorption of the study medication Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption. Any contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment. History of gastrointestinal mal-absorption or gastric bypass surgery Previous bowel resection anticipated to affect drug absorption Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of this oral agent are not eligible Known gastrointestinal disease or condition that affects the absorption of GT0918. Active gastrointestinal conditions that are expected to impair absorption of orally administered medications Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents Significant gastrointestinal condition that could potentially impair the absorption or disposition of the drug Clinically significant gastrointestinal disease, digestive dysfunction, or surgery that would compromise absorption of oral administration of medications Patients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitis Patient has a history of gastrointestinal (GI) surgical procedures, non-surgical procedures or conditions that might interfere with the absorption or swallowing of the study drugs Gastrointestinal condition which could impair absorption of BVD-523 or inability to ingest BVD-523 Subjects with gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the investigator Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product; Patients with any severe gastrointestinal or metabolic condition that could interfere with absorption of oral medications Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post major bowel resection Gastrointestinal abnormality that would affect absorption of SGN-2FF Known gastrointestinal disease or procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease Patients who have a history of gastrointestinal surgery or other procedures that might in the opinion of the investigator, interfere with the absorption or swallowing of the study drug Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib. Any underlying condition that would significantly interfere with the absorption of an oral medication Unable to take oral medications or any medical condition that would interfere with the absorption of study medication capsules Gastrointestinal disease that precludes absorption Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g, gastric bypass surgery, gastrectomy) Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety Gastrointestinal diseases or conditions that could affect drug absorption Any underlying condition that would significantly interfere with the absorption of an oral medication Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy) Ability to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or other conditions that may hamper compliance and/or absorption of the study agent Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy) Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib Current or recent (within 3 months of study treatment administration) gastrointestinal disease or conditions that could interfere with the swallowing or absorption of study medication or inability to tolerate oral medication Have a condition that limits the ingestion or absorption of drugs administered by mouth Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorption Patients with gastrointestinal disease, or those who have had a procedure that is expected to interfere with the oral absorption or tolerance of BAL101553 (e.g., functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved upon anti-emetic supportive care), are ineligible Subjects with gastrointestinal abnormalities including inability to take oral\n medication, malabsorption or other conditions like chronic inflammatory bowel disease\n that may affect absorption. Any underlying condition that would significantly interfere with the absorption of an oral medication Malabsorption syndrome or chronic nausea that might hinder absorption and assessment of oral medication Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption Is unable to take oral medications, has a history of surgery that would interfere with the administration or absorption of oral medication, has malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of IP Or any condition that might affect the absorption of orally taken medication Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment. History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption. History of gastrointestinal condition that may affect drug absorption. known gastrointestinal disease or condition which may affect the absorption of ASN003; Any current or recent (within 3 months) gastrointestinal disease that could potentially impact the ability to swallow and/or absorb study drug (i.e., gastrointestinal surgery, malabsorption syndrome) Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of CUDC-907. Active gastrointestinal conditions that are expected to impair absorption of orally administered medications Unable to swallow oral medications, or has gastrointestinal condition deemed to jeopardize intestinal absorption. Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting Subjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption. Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis) Patients with gastrointestinal comorbidities that would affect intake or absorption of ponatinib Any underlying condition that would significantly interfere with the absorption of an oral medication Gastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drug Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug. Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy) Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib. Any gastrointestinal disease that could hinder the absorption of enzalutamide Any gastrointestinal disease that could hinder the absorption of enzalutamide Gastrointestinal condition which could impair absorption of study medication Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject; Gastrointestinal disease that would impact on drug absorption Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib Gastrointestinal disease that interferes with receipt of oral drugs; Gastrointestinal disease that would impact on drug absorption Gastrointestinal conditions that could affect drug absorption including post surgical states such as gastric bypass Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug. Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption Gastrointestinal disease that may interfere with drug absorption. Significant active gastrointestinal disease that might impair absorption of study therapy; Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication. Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug. Gastrointestinal (GI) condition that could interfere with the swallowing or absorption of study medication Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. An upper gastrointestinal or other condition that would impair swallowing or absorption of oral medication Active gastrointestinal (GI) conditions that might predispose to drug intolerance or poor drug absorption Gastrointestinal condition which could interfere with the swallowing or absorption of study drug. Any underlying condition that would significantly interfere with the absorption of an oral medication History of gastrointestinal condition that might interfere with drug absorption Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption Any major surgery or gastrointestinal disease that would interfere with administration of oral medications Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication. Gastro-intestinal abnormalities that could affect the absorption of study drug. Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug. Gastrointestinal condition which could impair absorption of study medication Clinically significant gastrointestinal abnormality that would affect absorption of the drug Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent. Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption. Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs. Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug Inability to absorb abiraterone after oral administration (i.e., previous major gastrointestinal surgery or gastrointestinal disease resulting in malabsorption) g.i. condition that would prevent ingestion or absorption of 5-FC gastrointestinal impairment or disease that may interfere with drug absorption Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug. Ongoing gastrointestinal medical condition such as Crohn’s disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication Any underlying condition that would significantly interfere with the absorption of an oral medication Gastrointestinal conditions that may significantly affect the absorption of regorafenib Patients with a condition that, in the opinion of the investigator, would interfere with the absorption of oral medication will be excluded from the study Patient has any other condition that, in the opinion of the investigator, may impact the absorption of oral medications Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus Any other condition that, in the opinion of the investigator, may impact the absorption of oral medications Individuals with prior gastric bypass surgery or procedure that would impair absorption of nutrients Patients with known gastrointestinal conditions that could potentially interfere with absorption of orally administered medications Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment. History or current evidence of gastrointestinal malabsorption which, in the opinion of the investigator, may affect the extent of absorption of pritelivir. Inability to take oral medication, or presence of a malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability of H3B-6527. Participants with prior gastric resection are eligible History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorption History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kava Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.